INDI® SECURES CONTRACTS FOR XPRESYS® LUNG WITH MULTIPLAN AND FIVE OTHER PPOs; BLOOD TEST FOR PULMONARY NODULES NOW AVAILABLE TO 200 MILLION COVERED LIVES
NOVEMBER 5, 2014 – Indi® (Integrated Diagnostics), an emerging leader in molecular diagnostics, today announced that the company has secured contractual agreements with MultiPlan and five other PPOs (preferred provider organizations) for Xpresys® Lung, the first non-invasive molecular blood test for the assessment of pulmonary nodules. The other PPOs are: FedMed, Fortified Provider Network, InterWest Health, Stratose, and Three Rivers Provider Network. Together, these managed care organizations provide access to more than 130 million insured lives; combined with Indi’s existing commercial insurance contracts the test is now available to well over 200 million insured lives.
“These contracts demonstrate the game-changing clinical and economic value that Xpresys Lung offers,” said Albert A. Luderer, Ph.D., chief executive officer, Indi. “Indi’s test is designed to help physicians more confidently identify lung nodules as likely benign, reducing the need for unnecessary invasive procedures and their attendant risks, saving money, and lowering patient anxiety. We are confident the cost savings associated with Xpresys Lung will assist with the efforts of providers and carriers to secure ‘pay-for-performance’ incentives under the Affordable Care Act.”
Xpresys Lung is a breakthrough protein expression blood test developed to provide physicians with a solution to a major medical dilemma in the United States—the overtreatment of benign lung nodules. Today, it is estimated millions of pulmonary nodules are discovered each year; after traditional assessment protocols, which include biopsies and surgeries, most of these nodules are classified as benign. Xpresys Lung allows for the non-invasive assessment of pulmonary nodules in the 8-30 mm size range; traditionally, nodules of this size are associated with significant diagnostic uncertainty. Xpresys Lung provides physicians with objective information to identify nodules with a high probability of being benign, potentially reducing unnecessary invasive procedures which may be risky for the patient and costly to the healthcare system.
The blood test measures the relative abundance of proteins from multiple pathways associated with lung cancer, using a highly sensitive analytic technique called multiple reaction monitoring mass spectroscopy (MRM-mass spec).
Data from two studies supporting the technology behind Xpresys Lung were published in Science Translational Medicine on October 16, 2013. Click here to access the full study.
Indi (Integrated Diagnostics) is redefining molecular diagnostics and creating powerful new tools for physicians to non-invasively assess and more effectively manage complex diseases to improve patient outcomes, reduce complications, and lessen costs to the healthcare system. With the company’s first breakthrough test, Xpresys Lung, which measures multiple blood proteins and identifies lung nodules with a high probability of being benign, physicians have the potential to reduce risks and the need for unnecessary invasive procedures.
The company was co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, who recently received the National Medal of Science from the U.S. government. His groundbreaking research is based on a systems biology approach, which measures hundreds of protein biomarkers found in blood to report on the physiological state of the body’s 50 major organs, such as the lungs.
Backers include Baird Capital, InterWest Partners, Life Sciences Alternative Financing and the Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com